FIXX - Why Is Rare Disease Focused Homology Medicines Stock Trading Lower Today? | Benzinga
Q32 Bio Inc and Homology Medicines Inc (NASDAQ: FIXX) have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
The combined company will focus on advancing Q32 Bio's wholly-owned clinical development candidates for autoimmune and inflammatory diseases.
Upon completion of the merger, the combined company will operate as Q32 Bio, headquartered in Waltham, Massachusetts, and is expected to trade under ...